Yanan Zhu
Stock Analyst at Wells Fargo
(4.55)
# 1,032
Out of 5,058 analysts
454
Total ratings
35.5%
Success rate
14.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Reiterated: Buy | $102 | $67.13 | +51.94% | 1 | Oct 15, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $65 | $29.64 | +119.30% | 4 | Oct 15, 2026 | |
| EDIT Editas Medicine | Upgraded: Buy | $4 → $6 | $2.44 | +145.90% | 26 | Oct 8, 2026 | |
| BEAM Beam Therapeutics | Reiterated: Buy | $70 | $24.73 | +183.06% | 24 | Oct 2, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Hold | $75 | $51.52 | +45.57% | 17 | Oct 2, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $105 | $63.92 | +64.27% | 3 | Oct 2, 2026 | |
| ENGN enGene Therapeutics | Reiterated: Hold | $2 | $1.71 | +16.96% | 20 | Oct 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $45 → $55 | $20.62 | +166.73% | 5 | Oct 2, 2026 | |
| RNA Atrium Therapeutics | Reiterated: Buy | $25 | $7.81 | +220.10% | 4 | Oct 2, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $38 | $17.79 | +113.60% | 17 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 | $80.10 | +43.57% | 17 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 → $18 | $14.72 | +22.28% | 28 | Sep 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $87 | $79.94 | +8.83% | 1 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $22.52 | +233.04% | 29 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 | $11.46 | +327.57% | 1 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $2.24 | +123.21% | 1 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $20.72 | +189.58% | 2 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 | $44.12 | +115.32% | 46 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 → $7 | $0.8452 | +728.21% | 15 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $400 | $374.08 | +6.93% | 3 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.1409 | - | 22 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 | $11.34 | +32.28% | 26 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.73 | +194.91% | 28 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $11.27 | +77.46% | 26 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.72 | +190.70% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.11 | +261.99% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2.5 | $1.93 | +29.87% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1 | $0.0333 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0003 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.06 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $21.30 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 → $30 | $2.18 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $272 → $326 | $846.27 | n/a | 4 | Feb 2, 2021 |
BridgeBio Pharma
Oct 15, 2026
Reiterated: Buy
Price Target: $102
Current: $67.13
Upside: +51.94%
Pharvaris
Oct 15, 2026
Reiterated: Buy
Price Target: $65
Current: $29.64
Upside: +119.30%
Editas Medicine
Oct 8, 2026
Upgraded: Buy
Price Target: $4 → $6
Current: $2.44
Upside: +145.90%
Beam Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $70
Current: $24.73
Upside: +183.06%
CRISPR Therapeutics AG
Oct 2, 2026
Reiterated: Hold
Price Target: $75
Current: $51.52
Upside: +45.57%
Cytokinetics
Oct 2, 2026
Reiterated: Buy
Price Target: $105
Current: $63.92
Upside: +64.27%
enGene Therapeutics
Oct 2, 2026
Reiterated: Hold
Price Target: $2
Current: $1.71
Upside: +16.96%
NewAmsterdam Pharma Company
Oct 2, 2026
Reiterated: Buy
Price Target: $45 → $55
Current: $20.62
Upside: +166.73%
Atrium Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $25
Current: $7.81
Upside: +220.10%
Sarepta Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $38
Current: $17.79
Upside: +113.60%
Oct 2, 2026
Reiterated: Buy
Price Target: $115
Current: $80.10
Upside: +43.57%
Sep 30, 2026
Rated: Buy
Price Target: $14 → $18
Current: $14.72
Upside: +22.28%
Sep 29, 2026
Reiterated: Buy
Price Target: $87
Current: $79.94
Upside: +8.83%
Sep 29, 2026
Reiterated: Buy
Price Target: $75
Current: $22.52
Upside: +233.04%
Sep 29, 2026
Reiterated: Buy
Price Target: $49
Current: $11.46
Upside: +327.57%
Sep 29, 2026
Reiterated: Hold
Price Target: $5
Current: $2.24
Upside: +123.21%
Aug 31, 2026
Reiterated: Buy
Price Target: $60
Current: $20.72
Upside: +189.58%
Aug 14, 2026
Reiterated: Buy
Price Target: $95
Current: $44.12
Upside: +115.32%
Aug 11, 2026
Rated: Buy
Price Target: $9 → $7
Current: $0.8452
Upside: +728.21%
Aug 6, 2026
Reiterated: Buy
Price Target: $400
Current: $374.08
Upside: +6.93%
Jun 25, 2026
Rated: Hold
Price Target: n/a
Current: $0.1409
Upside: -
May 12, 2026
Reiterated: Hold
Price Target: $15
Current: $11.34
Upside: +32.28%
May 7, 2026
Reiterated: Buy
Price Target: $11
Current: $3.73
Upside: +194.91%
Mar 4, 2026
Reiterated: Buy
Price Target: $20
Current: $11.27
Upside: +77.46%
Jan 14, 2026
Reiterated: Buy
Price Target: $5
Current: $1.72
Upside: +190.70%
Jan 13, 2026
Reiterated: Hold
Price Target: $4
Current: $1.11
Upside: +261.99%
Jan 5, 2026
Reiterated: Hold
Price Target: $2.5
Current: $1.93
Upside: +29.87%
May 14, 2025
Reiterated: Hold
Price Target: $1.5 → $1
Current: $0.0333
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0003
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $10
Current: $2.06
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $21.30
Upside: n/a
Aug 16, 2023
Reiterated: Hold
Price Target: $45 → $30
Current: $2.18
Upside: n/a
Feb 2, 2021
Reiterated: Hold
Price Target: $272 → $326
Current: $846.27
Upside: n/a